Amgen's Kineret Arthritis Product Being Watched By Medco For Cost Impact
Executive Summary
Merck-Medco anticipates FDA approval for Amgen's rheumatoid arthritis treatment Kineret as early as the first quarter of 2001. The PBM is keeping close track of development of the drug as one of a handful of R&D projects that could have a significant impact on drug spending when they reach the market.
You may also be interested in...
Rx Cost Management Should Emphasize Generics Over Rebates - BC/BS Exec
The goal for pharmacy managers should be a decline in drug budgets over the next few years in light of patent expirations, Regence Blue Shield of Idaho Assistant VP-Pharmacy Services Terrance Killilea told the Pharmaceutical Benefit Management Institute April 28 in Scottsdale, Ariz.
Rx Cost Management Should Emphasize Generics Over Rebates - BC/BS Exec
The goal for pharmacy managers should be a decline in drug budgets over the next few years in light of patent expirations, Regence Blue Shield of Idaho Assistant VP-Pharmacy Services Terrance Killilea told the Pharmaceutical Benefit Management Institute April 28 in Scottsdale, Ariz.
Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn
Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.